The Food and Drug Administration (FDA) announced today that a drug called CTL019 has become the first chimeric antigen receptor (CAR) T-cell therapy approved to treat a form of cancer. The decision means the drug can be used as standard therapy for the treatment of pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL) … Read more
CAR T-cell therapy is a form of immunotherapy in which patients’ T cells are modified to become better at tracking down and destroying tumor cells. CAR T cells are made by extracting thousands of a patient’s T cells, sending them to a lab where they’re outfitted with genes and proteins that improve their cancer-fighting prowess, and … Read more
In the high-stakes contest of hide-and-seek between cancer cells and the human immune system, the advantage doesn’t always lie with the body’s defenders. A new approach to treatment, known as CAR T-cell therapy, may shift that balance of power. Cancer cells conceal themselves from the immune system not by barricading themselves in an impenetrable shell, … Read more
CAR T-cell therapy is a kind of cellular therapy, which uses a patient’s own immune system T cells to rally an attack on cancer. CAR T cells are made by removing T cells from the blood, modifying them in a lab to intensify the immune system’s natural response to cancer, and re-injecting them into the patient. CAR … Read more
Mark W. Kieran, MD, PhD, director of Pediatric Medical Neuro-Oncology at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, spoke to pediatric patient families in a recent Facebook Live Webchat addressing pediatric brain tumor care. Kieran answered questions from audience members about the most common of the 300 brain tumor types that occur in children, including … Read more